view set favor expect ew acceler ww thv sale growth
upcom investor day provid investor increas optim
potenti ew transcathet mitral program tavr franchis growth
trajectori risk data drive stronger tavr trend ew
best posit benefit market acceler
investor day unveil guidanc provid updat promis mitral program
expect next week decemb edward investor confer
least support recent momentum ew share expect top bottom line
guidanc rang bracket consensu estim well receiv street
number appear highli achiev post-coapt data era investor
sentiment toward ew transcathet mitral valv repair replac program
understand improv manag like provid detail roadmap
multipl clinic develop program well refresh view tmvr
expect mitral updat enhanc investor sentiment even
expect manag put forward similar revenu growth guidanc rang
provid anticip forecast call corpor wide
top line growth includ ww tavr growth growth surgic valv
growth critic despit challeng comp rang
bracket consensu estim leav room perform top end
rang investor focu ww tavr growth anticip
conservat experi manag consist state publicli
see sustain mid-teen ww tavr market growth trajectori
dont expect deviat histor messag risk data present
march ew like bake late fda approv assumpt
could leav room upsid check suggest posit non-inferior low
risk data drive creep front approv could push ww tavr market
growth north bear debat low risk creep alreadi play
role camp continu believ low risk data drive
least ramp inflect tavr util intern
ew bottom line target expect similar strategi employ
includ low dd ep growth midpoint rang would bracket
consensu estim top end rang ep growth appear
pleas see page report import disclosur
base outperform rate belief sustain ew high-single-digit
double-digit top-lin growth along double-digit ep growth trajectori driver
compani includ tavr market leadership age global elderli popul shift
aortic stenosi risk curv tavr rais tavr awar among patient
expect last year fda ce mark approv sapien intermedi risk aid
upsid trial prove favor believ ew share continu valu
premium median forward price-to-earnings multipl compani large-cap peer churn
centera sapien ultra ce launch
intermedi risk market develop
wake surtavi data readout
updat mitral program timelin
maintain market share
us tavr market
strong adopt sapien high-risk/
inoper patient us
continu success roll-out sapien
intermedi risk
top-lin growth acceler
ew mitral program develop faster
top-lin growth deceler
expect
ew lead medic devic compani manufactur heart valv repair
product replac repair diseas defect heart compani also provid
hemodynam monitor system cardiovascular function measur hospit
set headquart irvin california ew oper roughli countri
employe world-wide compani found edward
laboratori acquir baxter spun baxter earli
ew sale product world-wide posit
manag state detail tmvr program progress
expect investor day posit coapt data substanti
tmvr opportun histor strategi pursu replac repair platform
valid ew well posit tmvr categori repair
side fenc ew promis cardioband mitral annulu platform although
sputter gate eu due necessari shift manufactur ew facil
pascal edge-to-edg repair system behind abbott mitraclip
alreadi put stake ground call degen mitral opportun
patient per devic translat market opportun
 function mitral opportun doubl tripl number indic patient
get total tmvr alon ew put forward ww tmvr
like learn manag updat view opportun
live post-coapt world ew pascal expect launch eu
point clasp data made public around mid-year manag
may provid clariti time roll increment pascal
revenu add ww thv growth contribut meaning
pascal kick clasp iid trial pma studi investig
degen mitral indic patient prohibit risk mitral valv surgeri
enrol rct mitraclip control pascal clinic develop
path forward function mitral indic hasnt delin like
address investor day expect studi ultim incorpor similar head
head design mitraclip control
replac side fenc ew strategi deliber move
forward transsept platform play well two shot
goal evoqu sapien although theoret increment risk
replac system develop program due high efficaci safeti bar set
mitraclip coapt trial continu believ replac technolog
role transsept approach ultim win also expect complet
reduct mitral regurgit mr vs serv least segment
mitral patient popul deliv replac platform repair
intervent leav residu mr manag like provid updat clinic
develop pathway replac program expect investor sentiment
surround ew mitral prospect well multi-lay low risk mitral repair
mitral replac multi-year growth stori take step forward
favor set provid posit data point front risk
ww tavr forecast repres cc growth sequenti
growth view achiev level perform would repres stabl
perform rel cc growth experienc sequenti
growth acceler declin believ ww tavr estim least
reachabl light multipl tailwind play ew tavr franchis forecast
 tavr revenu repres growth sequenti
growth ou tavr number repres report growth
cc doubl digit sequenti growth continu
access program low risk cap kick late centera exceed pma
trial start enrol octob thu provid clinic revenu tailwind
low risk cap case quarterli run rate intermedi risk cap
would deliv sale sequenti ww tavr growth centera
trial singl arm intermedi risk trial enrol patient within year
could deliv level clinic tavr revenu similar low risk cap
sale receiv modest boost centera launch
describ target commerci introduct eu well sapien
ultra control roll-out ce mark novemb thu de minimu contribut expect
japan shown sign slow contribut nice
ew share momentum continu multipl posit catalyst horizon
increas price target given increas convict
upsid forecast ew ou tavr unit expect correl
flow bottom line pt partial base dcf analysi valu
edward base savr critic tavr busi new pt impli
adjust ep estim signific premium median multipl larg cap
medic devic peer exclud ew remain optimist
strengthen util trend intermedi risk indic contribut new
centera ultra valv potenti increas level creep upon posit low
risk data bigger boost low risk approv drive acceler growth
ew tavr franchis ew extrem well posit transcathet
mitral opportun recent valid coapt data believ stock
momentum sustain continu strong ww ultra centera trend
posit updat mitral tricuspid program along initi
contribut pascal europ begin believ
data posit event rubber meet road low
risk opportun offici unlock enhanc investor sentiment given
backdrop ew uniqu sustain strong multi-year growth profil
compani report thomson eikon cowen compani
good dilut share tax forma net forma ep incl net ep analysisgross analysistot forma cowen
compani report thomson eikon cowen compani
compani report thomson eikon cowen compani
usecent tavr enu cardioband enu total enu growth tavr enu growth cardioband growth trial/hd usequarterli clinic trial usecent commerci total commerci growth total enu growth q/q enu growth q/q non-royalti enu growth q/q pure commerci enu growth trial usequarterli clinic trial usecent commerci total worldcommerci usecent world ww enu cowen
valuat methodolog primarili base current year forward year ev/sal
ev/ebitda multipl well current year forward price-to-earnings multipl total return/p
ratio market cap/fre cash flow metric dividend yield comp
continu util pressur account organ play bigger
role health care deliveri competit dynam global potenti regulatori delay
reject failur devic clinic trial econom sensit price pressur
and/or weaken consum demand develop market econom and/or polit
uncertainti emerg market intellectu properti challeng
potenti regulatori delay reject failur devic clinic trial econom
sensit price pressur and/or weaken demand develop market econom
and/or polit uncertainti emerg market setback develop tmvr
product prevent commerci fluctuat foreign exchang rate
